The children who progressed to TID tended to have an initial IA-2 JM epitope response more frequently (= 006), and this response was more often dominant during the observation period (< 005). domain) and isotype-specific IA-2 antibodies. Individual areas under the curve (AUC) over the observation period were calculated for total IA-2 antibodies, each isotype and specific epitope responses. The children who progressed to TID tended to have an initial IA-2 JM epitope response more frequently (= 006), and this response was more often dominant during the observation period (< 005). The children who did not progress to TID had IgE-IA-2 more frequently (70%; progressors 27%; < 005), and had higher integrated titres of IgE-IA-2 antibodies (< 005). The occurrence of IgE-IA-2 antibodies was protective even when combined with positivity for IA-2 JM antibodies (= 0002). IgE-IA-2 antibody reactivity may be a marker of a regulatory immune response providing protection against or delaying progression to TID among IA-2 antibody-positive young children with HLA-conferred disease susceptibility. Keywords: type I diabetes, IA-2 antibody, epitope and isotype Introduction Type I diabetes (TID) is a chronic autoimmune disease characterized by silent destruction of the -cells in Mepixanox the pancreatic islets of Langerhans. During this asymptomatic destructive process, which usually continues for years, various autoantibodies to islet cell autoantigens can be detected as a sign of an ongoing T-cell mediated process, e.g. the related protein tyrosine phosphatase (PTP)-like molecules, islet antigen (IA)-2 and IA-2 [1]. Antibodies to the intracellular portion of the IA-2/IA-2 molecule have been shown to be the most predictive ones in relation to TID [2C4]. Autoantibodies specific for the IA-2 Mepixanox JM (juxtamembrane) region, the IA-2 PTP-like domain name, and the IA-2 PTP-like domain name have been identified, as also autoantibodies that are cross-reactive between the IA-2 and IA-2 PTP-like domains [2C7]. The changes acknowledged in the isotype profile of antigen-specific autoantibodies may also mirror the maturation of that response, as the isotypes might indirectly reflect the T-helper 1/T-helper 2 (Th1/Th2) balance of -cell autoimmunity [8C10]. It has been speculated that islet cell autoimmunity may start as a nonpathogenic Th2 response to the -cells, but turn into a pathogenic and destructive Th1 response leading to TID [11C13]. The natural history of preclinical diabetes is usually partly characterized, but still we have limited information on the dynamics of the immune response to -cell autoantigens during the course of preclinical disease. The aim of this work was to assess the maturation of the humoral immune response to Mepixanox IA-2 antibodies in preclinical TID by timing the emergence of various isotypes (IgG subclasses, IgM, IgA, IgE) of IA-2 antibodies, and observe possible indicators of epitope spreading within the molecule after the initial appearance of such antibodies in genetically susceptible young children identified from the general population. This could provide more sensitive and specific markers for discriminating between early and later stages of preclinical TID. Subjects and methods Subjects The series was derived from the Finnish Type I Diabetes Prediction and Prevention (DIPP) Study, which is a large ongoing population-based survey of genetically Foxd1 susceptible individuals aimed at studying the natural course of preclinical TID and assessing the predictive value of various immune and genetic risk markers in the general population [14]. According to the protocol, all newborn infants carrying HLA DQB1 genotypes conferring susceptibility to TID were observed from birth for the appearance of diabetes-associated autoantibodies. Islet cell antibodies (ICA) are used for primary screening of -cell autoimmunity. If a child seroconverts to positivity for ICA, antibodies to insulin (IAA), glutamic acid decarboxylase 65 (GAD65Ab) and the protein tyrosine phosphatase-related IA-2 protein are analysed in all available samples from birth, and the children in all centres are monitored at 3-month intervals after ICA seroconversion. The protocol has been approved by the local Ethics Committees, and the parents of the children have given their written informed consent to participation. Eighty-four (10%) children of a total of 8433 had tested positive for IA-2 antibodies on at least one occasion 7 years after the start of the DIPP study, and 16 of these had progressed to overt TID during the period of prospective observation. Fifteen of them had an IA-2 antibody-positive serum sample available from more than one point in time, and these were included as cases in the present study. Among the rest of the 68 topics, we determined 30 kids who had continued to be nondiabetic (nonprogressors) and may be matched using the progressors for sex, HLA genotype, age group in Mepixanox the ultimate end of observation and IA-2 antibody-positive observation period. IA-2 antibody subclasses and epitope specificities had been analysed within the serum examples starting from time of which IA-2 Mepixanox antibodies had been first recognized, or from the prior test onwards if obtainable (the mean age group at seroconversation to IA-2 antibody positivity was 22 years; range 10C48 years). Each young one who advanced to medical TID through the follow-up was noticed up to analysis, and each nonprogressor up to the test obtained in the corresponding age group. The mean age group of.